Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3701_Библиотеки_им_академика_М_И_Перельмана
.pdf
Novel Pathogenesis and Treatments for Cardiovascular Disease
61
https://t.me/medicina_free
[73] Rey M, Weber E, Hess PD.
Simultaneous pulmonary and systemic
blood pressure and ECG interval
measurement in conscious, freely
moving rats. Journal of the American
Association for Laboratory Animal
Science. 2012;(2):231-238
[74] Jiang M, Murias JM, Chrones T,
Sims SM, Lui E, Noble EG. American
ginseng acutely regulates contractile
function of rat heart. Frontiers in
Pharmacology. 2014;:43
[75] Imoto K, Hirakawa M, Okada M,
Yamawaki H. Canstatin modulates
L-type calcium channel activity
in rat ventricular cardiomyocytes.
Biochemical and Biophysical Research
Communications. 2018;(4):954-959
[76] Kruger C, Landerer V, Zugck C,
Ehmke H, Kubler W, Haass M. The
bradycardic agent zatebradine enhances
baroreflex sensitivity and heart rate
variability in rats early after myocardial
infarction. Cardiovascular Research.
2000;(4):900-912
[77] Dai GF, Wang ZJY. Octreotide
protects doxorubicin-induced cardiac
toxicity via regulating oxidative
stress. European Review for Medical
and Pharmacological Sciences.
2018;(18):6139-6148
[80] Trindade DC, Trindade RC,
Marassi MP, Martins OPPR, CostaE-Sousa RH, Mattos EC, etal. Role
of renin-angiotensin system in
development of heart failure induced
by myocardial infarction in rats. Anais
da Academia Brasileira de Ciências.
2007;(2):251-259
[81] Yenisehirli A, Naseri E. Omeprazole,
lansoprazole and pantoprazole had
no effect on blood pressure and
electrocardiogram of anesthetized
rat. Pharmacological Research.
2008;(1):65-71
[82] Parasuraman S, Raveendran R,
Selvaraj RJ. Effects of cleistanthins
a and B on blood pressure and
electrocardiogram in Wistar rats.
Zeitschrift für Naturforschung C.
2011;(11-12):581-587
[83] Kannan M, Quine SD. Ellagic acid
ameliorates isoproterenol induced
oxidative stress: Evidence from
electrocardiological, biochemical and
histological study. European Journal of
Pharmacology. 2011;(1):45-52
[84] Mutiso SK, Rono DK, Bukachi F.
Relationship between anthropometric
measures and early electrocardiographic
changes in obese rats. BMC Research
Notes. 2014;:931
[78] Mao PR, Jamali F. Methoxyflurane
anesthesia augments the chronotropic
and dromotropic effects of verapamil.
Journal of Pharmacy & Pharmaceutical
Sciences. 1999;(1):30-35
[79] Regan CP, Cresswell HK,
Zhang R, Lynch JJ. Novel method to
assess cardiac electrophysiology in
the rat: Characterization of standard
ion channel blockers. Journal of
Cardiovascular Pharmacology.
2005;(1):68-75
[85] Selcuk EB, Sungu M, Parlakpinar H,
Ermis N, Taslidere E, Vard N, etal.
Evaluation of the cardiovascular
effects of varenicline in rats. Drug
Design, Development and Therapy.
2015;:5705-5717
[86] Binu P, Priya N, Abhilash S,
Vineetha RC, Nair RH. Studies on curative
efficacy of monoterpene eugenol on
anti- leukemic drug arsenic trioxide
induced cardiotoxicity. Biomedicine &
Pharmacotherapy. 2017;:559-566

Rat Electrocardiography and General Anesthesia
DOI: http://dx.doi.org/10.5772/.104928
[87]
62
https://t.me/medicina_free
Bora S, Erdogan MA, Yigitturk G,
Erbas O, Parlak I. The effects of lipid
emulsion, magnesium sulphate and
metoprolol in amitriptylineinduced cardiovascular toxicity in
rats. Cardiovascular Toxicology.
2018;(6):547-556
[88]
Pişkin Ö, Ayoğlu H. Effects of
remifentanil pretreatment on bupivacaine
cardiotoxicity in rats. Cardiovascular
Toxicology. 2018;(1):56-62
[89]
Arini PD, Liberczuk S,
Mendieta JG, Santa María M, Bertrán GC.
Electrocardiogram delineation in
a Wistar rat experimental model.
Computational and Mathematical
Methods in Medicine. 2018;(3):1-10
[90]
Ramezani-Aliakbari F, Badavi M,
Dianat M, Mard SA, Ahangarpour A. The
effects of trimetazidine on QT-interval
prolongation and cardiac hypertrophy
in diabetic rats. Arquivos Brasileiros de
Cardiologia. 2019;(2):173-178
[91]
Sohrabi F, Dianat M, Badavi M,
Radan M, Mard SA. Does gallic acid
improve cardiac function by attenuation
of oxidative stress and inflammation in
an elastase-induced lung injury? Iranian
Journal of Basic Medical Sciences.
2020;:1130-1138
[92]
Boarescu PM, Boarescu I, Bulboacă AE,
Bocsan IC, Pop RM, Gheban D, etal.
Multi-organ protective effects of
curcumin nanoparticles on drug-induced
acute myocardial infarction in rats
with type 1 diabetes mellitus. Applied
Sciences. 2021;:5497
[93]
Miranda A, Costa-e-Sousa RH,
Werneck-de-Castro JP, Mattos EC,
Olivares EL, Ribeiro VP, etal. Time
course of echocardiographic and
electrocardiographic parameters
in myocardial infarct in rats. Anais
da Academia Brasileira de Ciências.
2007;:639-648
[94] Ketabchi F, Sepehrinezhad A,
Dehghanian A. The relationship between
liver dysfunction, electrocardiographic
abnormalities and metabolism in rat.
Journal of Clinical and Experimental
Cardiology. 2018;(10):1000610
[95] Kumar P, Verma S, Singh S,
Tiwari S, Khan MY. Effect of Aloe vera
(Aloe barbadensis) gel extract on
repolarization state of myocardium in
albino rat. African Journal of Pharmacy
and Pharmacology. 2010;(12):885-889
[96] Barrasa JLM, Rodriguez NS,
Rodriguez-Perez JC, Hidalgo AC,
Garcia AT, Camarillo JAI, etal.
Electrocardiographic changes in rats
undergoing thoracic surgery under
combined parenteral anesthesia. Lab
Animal. 2008;(10):469-174
[97] Sedmera D, Neckar J, Benes J Jr,
Pospisilova J, Petrak J, Sedlacek K, etal.
Changes in myocardial composition
and conduction properties in rat heart
failure model induced by chronic volume
overload. Frontiers in Physiology.
2016;:367
[98] Yadav RK, Rawat JK, Gautam S,
Singh M, Kumar M, Ansari MN, Roy S,
Saeedan AS, Kaithwas G. Antidiabetic
activity of mefloquine via GLP-1 receptor
modulation against STZ-NA-induced
diabetes in albino wistar rats. 3 Biotech
2018;8(5), 1-10
[99] Normann SJ, Priest RE, Benditt EP.
Electrocardiogram in the normal rat and
its alteration with experimental coronary
occlusion. Circulation Research.
1961;:282-287
[100] Fraser RS, Harley C, Wiley T.
Electrocardiogram in the normal rat.

Novel Pathogenesis and Treatments for Cardiovascular Disease
63
https://t.me/medicina_free
Journal of Applied Physiology.
1967;(3):401-402
[101] Kela AK, Reddy IP, Thombre DB.
E.C.G. findings in normal rats and after
administration isoproterenol. Indian
Journal of Physiology and Pharmacology.
1980;(2):84-90
[102] Krandycheva VV, Kharin SN,
Shmakov DN. P-wave body surface
potential distribution in rats. Journal of
Electrocardiology. 2006;(1):
88-92
[103] Upaganlawar AA, Balaraman R.
Cardioprotective effects of
co-administration of pomegranate
extract and vitamin E on
electrocardiographic, biochemical and
apoptotic changes in isoproterenol
induced myocardial infarction in rats.
Pharmacologia. 2015;(5):178-185
[104] Farag NE, El-Kherbetawy MK,
Ismail HM, Abdelrady AM, Toraih EA,
Abdelbasset WK, etal. Differential effect
of three macrolide antibiotics on cardiac
pathology and electrophysiology in a
myocardial infarction rat model: Influence
on sodium Nav1.5 channel expression.
Pharmaceuticals. 2021;:597-603
[105] Taskin E, Kindap EK, Ozdogan K,
Aycan MBY, Dursun N. Acute
adriamycin-induced cardiotoxicity
is exacerbated by angiotension II.
Cytotechnology. 2016;(1):33-43
[106] Da Silva VJD, Neto EF, Salgado HC,
Junior RF. Chronic converting enzyme
inhibition normalizes QT interval
in aging rats. Brazilian Journal of
Medical and Biological Research.
2002;(9):1025-1031
[107] Walsh EP, Alexander ME, Cecchin F.
Chapter 12 - electrocardiography and
introduction to electrophysiologic
techniques. In: Nadas’ Pediatric
Cardiology. 2nd ed. Amsterdam: Elsevier
Inc; 2006. pp. 145-181
[108] Surawicz B, Knilans TK. Normal
electrocardiogram. PR interval. In:
Chou’s Electrocardiography in Clinical
Practice. 6th ed. Amsterdam: Elsevier
Inc; 2008
[109] Richig JW, Sleeper MM. PR
(PQ), QRS, QT, and other issues. In:
Electrocardiography of Laboratory
Animals. 2nd ed. London, UK: Academic
Press, Elsevier Inc; 2019
[110] Mauer DE, Naegeli B, Straumann E,
Bertel O, Frielingsdorf J. Quality of life
and exercise capacity in patients with
prolonged PQ interval and dual chamber
pacemakers: A randomized comparison
of permanent ventricular stimulation vs
intrinsic AV conduction. EP Europace.
2003;(4):411-417
[111] Portnov A. PQ interval extension.
Diseases of the heart and blood vessels
(cardiology). PQ interval extension:
symptoms, diagnosis, treatment
(iliveok.com). 2021.
[112] Lown B, Ganong WF, Levine SA.
The syndrome of short P-R interval
normal QRS complex and paroxysmal
rapid heart action. Circulation.
1952;:693-706
[113] Zada M, Lo Q , Trivedi SJ,
Harapoz M, Boyd AC, Devine K, etal.
Electrocardiographic characteristics and
their correlation with echocardiographic
alterations in fabry disease. Journal
of Cardiovascular Development and
Disease. 2022;(1):11
[114] Shumilova TE, Shereshkov VI,
Yanvareva IN, Nozdrachev AD. Peculiarities
of myocardial electrogenesis in
laboratory rats under conditions of
acute nitrite intoxication. Journal of
Evolutionary Biochemistry and Phys.
2010;(2):179-188

Rat Electrocardiography and General Anesthesia
DOI: http://dx.doi.org/10.5772/.104928
[115]
64
https://t.me/medicina_free
Sadeghi N, Saadatfard S, Dianat M,
Abedi H, Dehghani K. Combination
effects of gallic acid and cyclosporine
a during ischemia/ reperfusion on
rat electrocardiogram parameters
and arrhythmia. Physiology and
Pharmacology. 2021;:162-170
[116]
Damasceno DD, Lima MP,
Motta DF, Ferreira AJ, Quintão-Junior JF,
Drummond-Junior LR, etal. Cardiovascular
and eletrocardiographic parameters
after tonin administration in Wistar rats.
Regulatory Peptides. 2013;:30-36
[117]
Gohma H, Kuramoto T,
Kuwamura M, Okajima R, Tanimoto N,
Yamasaki K, etal. WTC deafness Kyoto
(dfk): A rat model for extensive
investigations of Kcnq1 functions.
Physiological Genomics. 2006;:198-206
[118]
Mamalyga ML. Heart rate regulation
at different levels of convulsive readiness.
Bulletin of Experimental Biology and
Medicine. 2013;(4):425-428
[119]
Adeyemi O, Parker N, Pointon A,
Rolf M. A pharmacological
characterization of electrocardiogram PR
and QRS intervals in conscious telemetered
rats. Journal of Pharmacological and
Toxicological Methods. 2020;:106679
of WBN/Kob rats. Laboratory Animals.
1990;(3):288-291
[123] Van Buren T, Schiereck P, De
Ruiter GJW, Gispen WH, De Wildt DJ.
Vagal efferent control of electrical
properties of the heart in experimental
diabetes. Acta Diabetologica. 1998;(1):
19-25
[124] Lee JK, Nishiyama A, Kambe F,
Seo H, Takeuchi S, Kamiya K, etal.
Downregulation of voltage-gated K+
channels in rat heart with right ventricular
hypertrophy. American Journal of
Physiology. Heart and Circulatory
Physiology. 1999;(5):H1725-H1731
[125] Barrett TD, Hayes ES, Yong SL,
Zolotoy AB, Abraham S, Walker MJA.
Ischaemia selectivity confers efficacy
for suppression of ischaemia-induced
arrhythmias in rats. European Journal of
Pharmacology. 2000;(3):365-374
[126] Ghelfi E, Ramos-Rhoden C,
Wellenius GA, Lawrence J, GonzalezFlecha B. Cardiac oxidative stress
and electrophysiological changes in
rats exposed to concentrated ambient
particles are mediated by TRP-dependent
pulmonary reflexes. Toxicological
Sciences. 2008;(2):328-336
[120]
Hamdy DA, Brocks DR.
Experimental hyperlipidemia causes
an increase in the electrocardiographic
changes associated with amiodarone.
Journal of Cardiovascular Pharmacology.
2009;:1-8
[121]
Patel JP, Brocks DR. Effect of
experimental hyperlipidaemia on
the electrocardiographic effects of
repeated doses of halofantrine in
rats. British Journal of Pharmacology.
2010;(6):1427-1440
[122]
Machidal K, Dol K, Kaburaki M,
Sugano S. Electrocardiographical findings
[127] Regan CP, Stump GL, Wallace AA,
Anderson KD, McIntyre CJ, Liverton NJ,
etal. In vivo cardiac electrophysiologic
and antiarrhythmic effects of an
isoquinoline IKur blocker, ISQ-1, in rat,
dog, and nonhuman primate. Journal
of Cardiovascular Pharmacology.
2007;(4):236-245
[128] Medeiros DM, Shiry LJ,
McCune SA. Marginal copper intakes
over a protracted period in genetically
and nongenetically susceptible heart
disease rats disturb electrocardiograms
and enhance lipid deposition. Nutrition
Research. 2005;(7):663-372

Novel Pathogenesis and Treatments for Cardiovascular Disease
65
https://t.me/medicina_free
[129] Medei E, Lima-Leopoldo AP,
Pereira-Junior PP, Leopoldo AS,
Campos DHS, Raimundo JM, etal. Could
a high-fat diet rich in unsaturated fatty
acids impair the cardiovascular system?
The Canadian Journal of Cardiology.
2010;(10):542-548
[130] Milliez P, Deangelis N,
Rucker-Martin C, Leenhardt A, Vicaut E,
Robidel E, etal. Spironolactone reduces
fibrosis of dilated atria during heart
failure in rats with myocardial
infarction. European Heart Journal.
2005;(20):2193-2199
[131] Haugan K, Lam HR, Knudsen CB,
Petersen JS. Atrial fibrillation in rats
induced by rapid transesophageal
atrial pacing during brief episodes of
asphyxia: A new in vivo model. Journal
of Cardiovascular Pharmacology.
2004;(1):125-135
[132] Nattel S, Shiroshita-Takeshita A,
Brundel BJ, Rivard L. Mechanisms of
atrial fibrillation: Lessons from animal
models. Progress in Cardiovascular
Diseases. 2005;:9-28
prophylactic effects of metoprolol,
diltiazem, and pilocarpine on
hypoglycemia induced prolongation of
QT interval. Cureus. 2021;(3):e14058
[137] Jain PG, Mahajan UB, Shinde SD,
Surana SJ. Cardioprotective role of FA
against isoproterenol induced cardiac
toxicity. Molecular Biology Reports.
2018;(5):1357-1365
[138] Sultan F, Kaur R, Mir AH,
Maqbool I, Lonare M, Singh D, etal.
Rosuvastatin and retinoic acid may act as
pleiotropic agents’ against β-adrenergic
agonist-induced acute myocardial
injury through modulation of multiple
signalling pathways. Chemico-Biological
Interactions. 2020;:108970
[139] Gogelein H, Ruetten H, Albus U,
Englert HC, Busch AE. Effects of the
cardioselective K-ATP channel blocker
HMR 1098 on cardiac function in
isolated perfused working rat hearts and
reperfusion. Naunyn-Schmiedeberg’s
Archives of Pharmacology. 2001;(1):
33-41
[133] Gupta C, Omanwar S, Bubber P,
Saidullah B. ECG alterations precedes
cardiac hypertrophy in rat model
of diabetes. Open Access Journal of
Toxicology. 2018;(5)
[134] Shamala S, Krishna KL.
Cardioprotective activity of fruit extracts
of momordica dioca roxb on doxorubicin
induced toxicity on rats. Science
International. 2013;(12):392-400
[135] Badole SL, Jangam GB, Chaudhari SM,
Ghule AE, Zanwar AA. L-glutamine
supplementation prevents the development
of experimental diabetic cardiomyopathy
in streptozotocin-nicotinamide induced
diabetic rats. PLoS One. 2014;(3):e92697
[136] Cagiltay E, Pouwels S, Erbas O,
Taskiran D, Tas SK, Aslan I. The
[140] Di Filippo C, D'Amico M,
Marfella R, Berrino L, Giugliano D,
Rossi F. Endothelin-1 receptor antagonists
reduce cardiac electrical instability
induced by high glucose in rats.
Naunyn-Schmiedeberg's Archives of
Pharmacology. 2002;(3):193-197
[141] Panoulas VF, Toms TE,
Douglas KMJ, Sandoo A, Metsios GS,
Stavropoulos-Kalinoglou A, etal.
Prolonged QTc interval predicts all-cause
mortality in patients with rheumatoid
arthritis: An association driven by high
inflammatory burden. Rheumatology.
2014;(1):131-137
[142] Jayasinghe R, Kovoor P. Drugs and
the QTc interval. Australian Prescriber.
2002;:63-65

Rat Electrocardiography and General Anesthesia
DOI: http://dx.doi.org/10.5772/.104928
[143]
66
https://t.me/medicina_free
Kmecova J, Klimas J. Heart rate
correction of the QT duration in rats.
European Journal of Pharmacology.
2010;(2-3):187-192
[144]
Rossing P, Breum L, MajorPedersen A, Sato A, Winding H,
Pietersen A, etal. Prolonged QTc interval
predicts mortality in patients with type
1 diabetes mellitus. Diabetic Medicine.
2001;(3):199-205
a single whole-body exposure to sarin
vapor in rats. Toxicological Sciences.
2005;:385-390
[151] Howden R, Hanlon PR, Petranka JG,
Kleeberger S, Bucher J, Dunnick J, etal.
Ephedrine plus caffeine causes agedependent cardiovascular responses
in Fischer 344 rats. American Journal
of Physiology Heart and Circulatory
Physiology. 2005;:H2219-H2224
[145]
Andršová I, Hnatkova K, Šišáková M,
Toman O, Smetana P, Huster KM, etal.
Sex and rate change differences in QT/RR
hysteresis in healthy subjects. Frontiers in
Physiology. 2022;:2473
[146]
Van Noord C, Eijgelsjeim M,
Stricker BHC. Drug- and non-drugassociated QT interval prolongation.
British Journal of Clinical Pharmacology.
2010;(1):16-23
[147]
Hayes E, Pugsley MK, Penz WP,
Adaikan G, Walker MJ. Relationship
between QaT and RR intervals in rats,
Guinea pigs, rabbits, and primates.
Journal of Pharmacological and
Toxicological Methods. 1994;:201-207
[148]
Tavakoli S, Hajrasouliha AR,
Jabehdar-Maralani P, Ebrahimi F,
Solhpour A, Sadeghipour H, etal. Reduced
susceptibility to epinephrine-induced
arrhythmias in cirrhotic rats: The
roles of nitric oxide and endogenous
opioid peptides. Journal of Hepatology.
2007;:432-439
[152] Lamb CM, Hazari MS, Haykal-
Coates N, Carll AP, Krantz QT, King C,
etal. Divergent electrocardiographic
responses to whole and particle-free
diesel exhaust inhalation in spontaneously
hypertensive rats. Toxicological Sciences.
2012;(2):558-568
[153] Nwokocha C, Palacios J,
Simirgiotis MJ, Thomas J, Nwokocha M,
Young L, etal. Aqueous extract from
leaf of Artocarpus altilis provides
cardio-protection from isoproterenol
induced myocardial damage in rats:
Negative chronotropic and inotropic
effects. Journal of Ethnopharmacology.
2017;:163-170
[154] Mohammed HS, Hosny EN,
Khadrawy YA, Magdy M, Attia YS,
Sayed OA, etal. Protective effect
of curcumin nanoparticles against
cardiotoxicity induced by doxorubicin
in rat. Biochimica et Biophysica Acta
(BBA) - Molecular Basis of Disease.
1866;(5):165665
[149]
Volk T, Nguyen TH, Schultz JH,
Faulhaber J, Ehmke H. Regional alterations
of repolarizing K
+
ventricular free wall of rats with ascending
aortic stenosis. The Journal of Physiology.
2001;:443-455
[150]
Allon N, Rabinovitz I, Manistersky E,
Weissman BA, Grauer E. Acute and
long-lasting cardiac changes following
currents among the left

Chapter 3
67
https://t.me/medicina_free
G Protein-Coupled Receptor
Regulation in Cardiovascular
Disease: Role of G Protein-Coupled
Receptor Kinases
Asma S.Alonazi, Anfal F.Bin Dayel, Tahani K.Alshammari
and Nouf M.Alrasheed
Abstract
G pr
otein-coupled receptor kinases (GRKs), the negative regulators of G proteincoupled receptors (GPCRs), have a key role in cardiovascular disease pathophysiology.
Alteration in GRKs’ expressions and/or kinase activity has been reported in preclinical
animal models as well as in patients with cardiovascular diseases. This alteration might
be a contributing factor to disease progression by a variety of mechanisms such as noncanonical transduction pathways. The current chapter is aimed to expand our knowledge and understanding of the function of GRKs in cardiovascular diseases, highlight
their involvement, and illustrate the possible mechanistic role of GRKs in hypertensive
vascular diseases and cardiac myopathy. The current chapter also is endeavoured to
identify the potential molecular mechanisms by which GRKs participate in cardiovascular disease progression. Building the basics knowledge about GRKs in cardiovascular
diseases will help to assess the potential utilization of GRKs as therapeutic targets and
to examine the possible approaches to modulate their protein expression or to inhibit
their kinase activity to prevent or attenuate cardiovascular disease progression.
Keywords: GRK2, GRK5, GPCR regulation, cardiovascular diseases, heart failure,
hypertension, myocardial infarction
. Introduction
Cardiovascular diseases consider as one of the major causes of death, contributing to
approximately 30% of all deaths globally. In Kingdom of Saudi Arabia, approximately
37% deaths are caused by cardiovascular diseases [1]. Elevated cardiovascular diseaserelated morbidity and mortality result from a complex pathophysiological process
including activation of many signaling transduction pathways, resulting in modification in cardiac/vascular structure, remodeling, and ultimately alteration in the functionality, which contributes to disease progression. Of importance, G protein-coupled
receptors (GPCR) play a key fundamental role in various transductions signaling that
participate in cardiovascular diseases pathophysiological progression. GPCRs are a

Novel Pathogenesis and Treatments for Cardiovascular Disease
68
https://t.me/medicina_free
superfamily of heptahelical integral membrane proteins, which respond to various
stimuli. They are responsible for transduction of a plethora of signaling networks that
involve in physiological and pathological actions in cardiovascular system [2, 3]. The
activation of α-adrenergic, β-adrenergic, muscarinic, angiotensin II type 1 receptor
(AT1) and endothelin (ETA) receptors are involved in cardiac contractility, vascular
resistance, vascular and cardiac remodeling. In addition, the effect of neurohumoral
systems on cardiac contractility and blood vessel tone mainly transmit their signals via
corresponding GPCR. These types of receptors and their downstream transduction
systems are targets of various drugs used in the treatment of cardiovascular diseases [4].
In case of hypertension, GPCRs play fundamental function in blood vessel diameter, which is mainly controlled by either contraction or relaxation of vascular smooth
muscle cells. During contraction, GPCR mediated phosphorylation of contractile
proteins [5]. Vasoactive peptides such as noradrenaline, angiotensin II, endothelin 1,
and vasopressin activated their corresponding G
coupled GPCR, results in stimula-
αq
tion of phospholipase C-β, resulting in the formation of inositol-1,4,5-trisphosphate
(IP3) and diacylglycerol (DAG). IP3 binds to their corresponding receptors which is
inositol trisphosphate receptors (IP3Rs) in the sarcoplasmic reticulum; the intracellular Ca2+ store. Activation of IP3Rs resulting in efflux of Ca2+ into the cytoplasm.
On other hand, DAG activates protein kinase C (PKC), promoting Ca2+ influx via
enhancing the vascular channels activity such as voltage-dependent L-type Ca2+
channels. Elevated intracellular Ca2+ concentration [Ca2+]i binds to calmodulin,
creating Ca2+-calmodulin complex which activate MLC kinase (MLCK) followed by
phosphorylation of contractile proteins that promote myosin-actin filament interactions and consequently smooth muscle contraction [6–11]. Contraction of vascular
smooth muscle cells could persist via regulation of MLC phosphatase (MLCP).
Vasoactive peptides also regulate the dephosphorylation of MLC phosphatase via different mechanisms. They utilize the PLC-DAG-PKC pathway, which in turn inhibits
phosphatase activity and thus stimulates persistent contraction [12]. In addition,
they activate RhoA-Rho kinase pathway, which phosphorylates MLCP and inhibits
its activity [13, 14]. On the other hand, a low [Ca2+]i concentration and increased
activity of MLC phosphatase promoting vascular smooth muscle cell relaxation [15].
Gαs-coupled GPCR mediated blood vessel relaxation. Adrenaline, as vasodilator, acts
on corresponding receptors, recruiting Gαs to stimulate adenylyl cyclase (AC), leading
to the formation of cAMP and then activation of protein kinase A (PKA). PKA plays
important role in decreasing [Ca2+]i concentrations via phosphorylation of MLCK.
This results in activation of calcium pumps in the plasma membrane and sarcoplasmic reticulum. Furthermore, promotes cell hyperpolarization by opening K+ channels
promoting relaxation of vascular smooth muscle cells [8, 16, 17].
In case of heart failure, GPCR such as β-adrenergic receptors plays an essential
role in cardiac function and in cardiac myocytes contractility. β1-adrenergic receptors couple to Gαs that activates adenylate cyclase (AC) and enhances cAMP mediate
protein kinase A (PKA) activation which regulates different intracellular, sarcolemma, and myofibrillar substrates, mediating positive inotropic and chronotropic
effects [18]. G
subunits also activate downstream effectors that participate in
βγ
cardiac transduction pathways. Moreover, it has been reported that overexpression of
β1-adrenergic receptors triggers early myocytes hypertrophy and interstitial fibrosis
followed by marked cardiac dysfunction in mice [18]. In addition, β1-adrenergic
receptors activate various downstream signaling participating in cardiac pathophysiological processes such as cardiac hypertrophy, which might progress to heart failure
development [19–21]. β2-adrenergic receptors can couple to a dual G
αs/Gαi
subunits, it

G Protein-Coupled Receptor Regulation in Cardiovascular Disease: Role of G Protein-Coupled…
DOI: http://dx.doi.org/10.5772/.105403
has been implicated in differential β2-adrenergic receptors mediated signaling such as
69
https://t.me/medicina_free
in myocyte apoptosis [22]. Therefore, β-adrenoceptor blockers are one of the standard
pharmacotherapeutics agents used in the treatment of heart failure patients [23].
β-blockers also have been shown to reduce disease progression, mortality, and morbidity in patients with heart failure with reduced ejection fraction (HFrEF) [24]. This
effect appears primarily related to the ability of β-adrenoceptor blockers to protect
the heart from the harmful effects of receptor over-stimulation [25].
As the effect of neurohumoral systems on cardiovascular system mainly transmits
their signals via GPCRs, understanding of the GPCR regulation and their G-protein
dependent/independent signaling reveals a novel therapeutic approach that could
attenuate cardiovascular-related complications. In current chapter, we provide insight
into the potential effect of GPCR negative regulators, focusing particularly on G
protein-coupled receptor kinases (GRKs) and their possible effect on cardiovascular
diseases.
. GPCRs regulations
Repeated or prolonged/continues agonist stimulation of GPCRs resulted in loss
of receptor response characterized as receptor desensitization. It can be described
as physical uncoupling of G proteins from their associate receptors subsequent in
diminish their ability to initiate intracellular signaling cascades [26]. As shown in
Figure , receptor desensitization process is initiated by receptor phosphorylation. It
can be mediated by G protein-coupled receptor kinases (GRKs), which phosphorylate
agonist-bound active receptor inducing homologous type of receptor desensitization
[27]. Receptor phosphorylation can be also mediated by second messenger kinases
such as PKA and PKC, which can phosphorylate receptors regardless of whether the
GPCR is occupied by agonist or not, thus producing heterologous type of receptor
desensitization [27–29]. Receptor phosphorylation subsequently increases the affinity
of the receptors for β-arrestins proteins binding, consequently prevents further receptors-G protein interactions and therefore termination of G protein-related signaling
Figure 1.
GPCR desensitization and related signaling transductions pathways. GPCR desensitization by GRKs and
β-arrestins process initiated with ligand binding, receptor activation and dissociation of G protein. Consequently,
GRKs phosphorylate agonist-occupied GPCRs (activated receptors) at third intracellular loop or C-terminal.
Receptor phosphorylation resulting in enhances the affinity for β-arrestin recruitment then binding to the receptors
causing termination of G-protein dependent transduction signaling and receptor desensitization. After that, the
receptors undergo internalization and initiation of G protein-independent transduction signaling.

Novel Pathogenesis and Treatments for Cardiovascular Disease
70
https://t.me/medicina_free
[30]. Accordingly, the phosphorylated GPCR/β-arrestin complex is subjected for
clathrin-mediated endocytosis, followed by either recycling, or degradation [31–33].
Importantly, β-arrestins function as ligand-regulated adaptor scaffolds that enable the
transduction of signaling pathways in non-canonical manner [34].
. G protein-coupled receptors kinases (GRKs)
G Protein-Coupled Receptors Kinases (GRKs) are family of seven members of
serine/threonine kinases [35]. They are allocated into three subcategories: the first
category is visual GRKs including GRK1 and GRK7; the second and third categories
are non-visual GRKs including β-adrenergic receptor kinase subcategory, containing
GRK2 (β-ARK1) and GRK3 (β-ARK2) and; the GRK4 subcategory, containing GRK4,
GRK5, and GRK6 [27]. Regarding GRKs tissue distribution, GRK1 and GRK7 are
primarily expressed in the retina mediating photoreceptor regulation. GRK2, GRK3,
GRK5, and GRK6 are ubiquitously expressed in various tissues; however, GRK4 is
limitedly distributed to testes, kidneys, and some areas of the brain. Hence, GRK2,
GRK3, GRK5, or GRK6 is the potential regulator for the majority of GPCRs [36–38].
In cardiovascular system, the distribution pattern and expression levels of GRK
are crucial factors contributing to their functionality in various cell types. Previous
reports show that GRK2, GRK3, and GRK5 are highly expressed in the human heart
[39]. GRK isoforms distribution is different among various heart cells. GRK2 and
GRK5 are expressed in almost all cardiac cells, while GRK3 distribution is limited
to cardiac myocytes [4, 40]. GRK2 is expressed in the vascular endothelium, arterial smooth muscle, and in the myocardium. GRK2 is also expressed in the kidney,
especially in the renal proximal tubule [41].
The structure of GRKs comprises of three domains: N-terminal; an amino
terminal domain, central serine/threonine protein kinase/catalytic domain, and
C-terminal; a carboxyl terminal domain. The N-terminal domain is implicated in
receptor recognition. It includes a region of a regulator of G protein signaling (RGS)
homology domain (RH) [31, 35]. In GRK2, Gβγ binding site has been mapped in
the N-terminal region causing binding of GRK2 to cell membrane [42]. The central
domain is a serine/threonine protein that exerts the kinase catalytic function in all
GRKs. The C-terminal domain structure is different among GRKs subfamilies. It
is implicated in GRK membrane localization. For instant, GRK5 is located at cell
membrane level as the C-terminus of GRK5 contains lipid-binding sites that interact
with the phospholipid in the cell membrane. On other hand, GRK2 and GRK3 are
cytoplasmic proteins that are recruited to the plasma membrane upon agonist binding and receptor activation. Their C-terminal domains contain pleckstrin homology
(PH) domain, which comprises binding sites for the cell membrane phospholipid
(PIP2) and Gβγ subunits [26, 35, 43]. As a multi-domain protein, GRK acts as a
negative GPCR signaling regulator, terminating G protein-dependent signaling and
initiating other G protein-independent signaling pathways [30, 44]. For instance,
reported evidence reported that GRK functions are expanded more than receptors
phosphorylation. GRKs are able to interact with various cellular proteins mediating
non-canonical GPCR signaling [31, 45]. Of importance, GRK expression and activity
are changed in many cardiovascular diseases such as in case of hypertension or heart
failure. Thus, better understanding of the diseases associated with alteration in GRKs’
expression as well as their functional roles in cardiovascular system is fundamental to
develop a new therapeutic target.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
